Compare BZUN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | CNTB |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | United States |
| Employees | 6762 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 135.7M |
| IPO Year | 2014 | 2020 |
| Metric | BZUN | CNTB |
|---|---|---|
| Price | $2.88 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 230.1K | ★ 324.7K |
| Earning Date | 05-20-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $7.89 | N/A |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $1.23 |
| 52 Week High | $4.88 | $3.82 |
| Indicator | BZUN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 62.11 |
| Support Level | $2.61 | $2.27 |
| Resistance Level | $3.02 | $2.64 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 25.44 | 78.10 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.